JOHNSON & JOHNSON
CIK: 0000200406Latest portfolio: $554.6M · Q4 2025
Holdings
17
Total Value
$554.6M
New Positions
1
Closed Positions
4
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | PTGXProtagonist Therapeutics Inc. | 2,449,183 | $213.9M | 38.57% | — | |
| 2 | NBTXNanobiotix S.A. | 5,623,816 | $130.0M | 23.44% | — | |
| 3 | RAPPRapport Therapeutics, Inc. | 1,784,517 | $54.1M | 9.76% | — | |
| 4 | MGTXMeiraGTx Holdings plc | 6,641,064 | $52.8M | 9.52% | — | |
| 5 | CVRXCVRx, Inc. | 4,024,861 | $28.6M | 5.15% | -78,569 | |
| 6 | CTNMContineum Therapeutics Inc. | 1,979,173 | $22.6M | 4.08% | — | |
| 7 | LEGNLegend Biotech Corporation | 814,586 | $17.7M | 3.19% | — | |
| 8 | XNCRXencor, Inc. | 748,062 | $11.5M | 2.06% | — | |
| 9 | PRCTProcept BioRobotics Corporation | 357,939 | $11.3M | 2.03% | — | |
| 10 | FATEFate Therapeutics, Inc. | 3,379,064 | $3.3M | 0.60% | — | |
| 11 | NMRANeumora Therapeutics, Inc. | 1,849,445 | $3.3M | 0.60% | — | |
| 12 | RLYBRallybio Corporation | 3,636,363 | $2.5M | 0.45% | — | |
| 13 | LYELLyell Immunopharma, Inc. | 41,165 | $1.3M | 0.23% | — | |
| 14 | VORVor Biopharma, Inc. | 53,732 | $702K | 0.13% | — | |
| 15 | NNOXNano-X Imaging Ltd. | 158,852 | $444K | 0.08% | — | |
| 16 | FLBStandard BioTools, Inc. | 311,967 | $399K | 0.07% | — | |
| 17 | ACETAdicet Bio, Inc. | 22,779 | $191K | 0.03% | NEW |
Quarterly Changes
New Positions
- ACETNEW$191K
Increased Positions
No increased positions
Decreased Positions
| Name | Shares | Change |
|---|---|---|
| CVRX | 4.0M | -78569 |
Sector Breakdown
Healthcare0.0% ($2.1391113002254142e+62T)
Unknown0.0% ($399K)
Filing History
Fund Information
JOHNSON & JOHNSON is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $554.6M across 17 holdings. The largest position is Protagonist Therapeutics Inc. (PTGX), representing 38.6% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 4 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.